Drug intelligence / Profile preview

ADB-104

Development stage: Preclinical
Lead developer: Adolore Biotherapeutics
Modality: Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies

Overview

ADB-104 is a proprietary gene therapy candidate being developed by Adolore BioTherapeutics for the treatment of drug-resistant refractory focal epilepsy. It is part of Adolore’s pipeline focused on neurological disorders and chronic pain, leveraging innovative gene therapy vectors. While specific details about its mechanism of action or vector design have not been publicly disclosed, it is positioned as a novel, non-opioid therapeutic approach targeting unmet needs in severe epilepsy that does not respond to conventional treatments[1].

Targets

KCNQ (Potassium voltage-gated channel subfamily Q (Kv7))

Beyond the preview

Go deeper on ADB-104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADB-104.

Explore the full profile